Mounjaro contains tirzepatide, which acts at GIP and GLP-1 receptors. It is given once weekly and is available in single-dose and multidose presentations, with different device instructions.
The approved uses and formulations described here follow US prescribing information. They may differ in other countries.
| Medicine detail | Details |
|---|---|
| Active ingredient(s) | tirzepatide |
| Medicine class | GIP / GLP-1 receptor agonist |
| Forms and strengths | Weekly injection: 2.5, 5, 7.5, 10, 12.5 and 15 mg; single-dose and multidose presentations |
Approved uses in the United States
Mounjaro is approved alongside diet and exercise for glucose control in adults and children aged 10 years and older with type 2 diabetes. It is also approved to reduce major cardiovascular events in adults with type 2 diabetes at high risk of those events.
Source: [1]
Strength and device both matter
The six injection strengths range from 2.5 to 15 mg. The current label includes single-dose pens and vials, and four-dose multidose vials and KwikPens. Dose volume differs by presentation. Pediatric and adult maximum doses also differ, so the strength range is not an instruction for every patient. For more on dose schedules and presentations, read the Tirzepatide Dosing guide.
Source: [1]
The thyroid boxed warning
Tirzepatide caused thyroid C-cell tumors in rats; whether it causes these tumors in humans is unknown. Mounjaro must not be used by people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2).
Source: [1]
Other treatment considerations
Pancreatitis, serious gastrointestinal effects, dehydration-related kidney injury and gallbladder disease are among the warnings. The label advises additional or non-oral contraception for four weeks after starting and after each dose increase for people using oral hormonal contraceptives. Discuss pregnancy plans and procedures with the clinical team.
Source: [1]
Mounjaro and Zepbound
Both contain tirzepatide, but their approved uses differ. They require separate prescriptions and product-specific instructions. If the presentation supplied changes, check the product name and device with the pharmacist and ask for any training needed. Counterfeit products can also resemble legitimate injection pens; in October 2026, UK authorities seized more than 12,000 fake tirzepatide and retatrutide weight-loss pens. To explore differences from other medicines, use the Ozempic Vs Mounjaro Comparator or Wegovy Vs Mounjaro Comparator. For payment and coverage context, read the Ozempic Vs Mounjaro US cost comparison.
Source: [1]
Questions and answers
Can children be prescribed Mounjaro?
Its US glucose-control indication includes children aged 10 years and older with type 2 diabetes. The cardiovascular indication applies to specified adults.
Does every Mounjaro pen contain one dose?
No. The current label includes four-dose KwikPens as well as single-dose pens.
Is Zepbound simply another interchangeable Mounjaro pack?
No. The products share tirzepatide but have different approved uses and prescribing contexts.
Related reading
Sources
Sources checked 1 October 2026. This information does not replace advice from your healthcare professional. For complete warnings and instructions, read the product information and consult the prescribing team.
Reviewed by: Mattias Hagman, PhD
About the reviewer:
Dr Mattias Hagman (PhD, University of Sydney) has an academic background and experience working with healthcare-related content and regulated industries. He has lecturing experience at international universities, including Stockholm University and the University of Malta.
Last reviewed: October 2026